Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

No phase data available

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06840990Completed

Cross-linked CMC and Silk Proteins in Corneal Re-epithelization

Role: lead

NCT06728215Completed

Capacitive-Resistive Energy Transfer (CRET) for the Treatment of Low Back Pain

Role: lead

NCT06605365Completed

Cross-linked CMC and Silk Proteins in Eye Disease

Role: lead

NCT06573606Completed

Ophthalmic Solution in Diabetic Corneal Alteration

Role: lead

All 4 trials loaded